Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Animal Selected For Lacking Heparan Sulfate-3-O-Sulfotransferase-1 and Uses Thereof

a technology of heparan sulfate and sulfate, which is applied in the field of animals selected for lacking heparan sulfate-3-o-sulfotransferase-1 and uses thereof, can solve the problems of unclear whether hssup> is hs, the level of at activity is not clear, and the patient is predisposed to venous thrombosis

Inactive Publication Date: 2007-11-29
TRUSTEES OF DARTMOUTH COLLEGE THE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to an animal model for myxomatous valvular disease, which is a common heart valve disease in humans. The animal model is created by introducing a transgene containing 3-OST-1 nucleic acid sequences and a selectable marker into an animal. The resulting animal exhibits characteristics associated with myxomatous valvular disease. The invention also provides methods for screening for agents that can treat or prevent the disease, as well as diagnostic methods for detecting the presence of 3-OST-1 in a sample. The invention also includes a method for producing an antibody to 3-OST-1 protein.

Problems solved by technology

However, it is unclear whether HSact is a major physiologic modulator of hemostasis.
For example, mutations that reduce the level of AT activity primarily predispose patients to venous thrombosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Animal Selected For Lacking Heparan Sulfate-3-O-Sulfotransferase-1 and Uses Thereof
  • Animal Selected For Lacking Heparan Sulfate-3-O-Sulfotransferase-1 and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of Hs3st1 − / − Mice

[0071] The Hs3st1 coding region was isolated by PCR screening an arrayed P1 library of 129P2 / OlaHsd genomic DNA (Incyte Genomics, St. Louis, Mo.) with two different oligonucleotide sets designed to amplify 5′ and 3′ untranslated region sequences of Hs3st1. Primers 5′-dATTGGCAACTGGAGATACTCATGT (SEQ ID NO:1) and 5′-dTGCCTTCTCCGGTGTCCTCT (SEQ ID NO:2) amplify nucleotides 219-467; whereas, 5′-dTTCTGTACAGTATTAGATTCACAGT (SEQ ID NO:3) with 5′-dGCTATTTTGGATTGGAGGCAGGT (SEQ ID NO: 4) amplify nucleotides 1383-1617 from the mouse Hs3st1 cDNA sequence (Shworak, et al. (1997) supra). Three independent overlapping genomic clones were recovered, exons were mapped by Southern blot analysis and the coding region was verified by DNA sequence analysis to reveal that exon 8 contained the entire coding region.

[0072] A targeting construct was generated from pMCIDT-A which contains an expression cassette for diphtheria toxin A (DTA) for positive selection. The targeting con...

example 2

Characterization of 3-OST-1 Deficient Mice

[0076] All experimental animals were generated from Hs3st1+ / −×Hs3st1+ / − crosses. Experimental groupings employed age and sex matched littermates. Unless otherwise indicated, all data are expressed as the mean±S.E.M. and statistical significance was evaluated by two-tailed Student's t-test.

[0077] For analysis of T·AT complexes, immediately after arterial injury a 0.5 cc syringe containing 30 μl of 3.8% trisodium citrate was used to draw ˜300 μl blood by a single puncture of the left ventricle. Otherwise ˜170 μl of blood was collected, during tail tissue collection, in tubes containing 10 μl of 3.8% trisodium citrate. Plasma was prepared by two sequential centrifugations then frozen on liquid N2 and stored at −80° C. For determination of 3-OST-1 activity, 70 μl of fresh plasma was combined with 0.91 μl of 77 μg / ml pepstatin, 770 μg / ml leupeptin, 150 μg / ml aprotinin (Sigma, St. Louis, Mo.), and 77 mM PEFABLOC® SC (Boehringer Mannheim, Mannhei...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
structureaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

An animal selected for lacking heparan sulfate 3-O-sulfotransferase-1 activity is provided. This animal exhibits characteristics associated with myxomatous valvular disease and is useful for identifying agents which prevent, delay or treat myxomatous valvular disease. Methods of diagnosing myxomatous valvular disease are also provided.

Description

INTRODUCTION [0001] This invention was made in the course of research sponsored by the National Institutes of Health (NIH Grant No. PO1 HL41484-12). The U.S. government may have certain rights in this invention.BACKGROUND OF THE INVENTION [0002] Hemostatic tone is dynamically established as the net balance between ongoing procoagulant versus anticoagulant and fibrinolytic processes. Antithrombin (AT) is a major anticoagulant that slowly neutralizes proteases of the coagulation cascade through the formation of 1:1 enzyme·AT complexes. The rate of neutralization is dramatically enhanced by heparin, a variant of heparan sulfate (HS) from mast cells. It has been hypothesized that heparan sulfate proteoglycans (HSPGs) on the endothelial cell surface might similarly accelerate AT activity and thereby contribute to the nonthrombogenic properties of blood vessels (Damus, et al. (1973 Nature 246:355-357). Indeed, the perfusion of purified thrombin (T) and AT into the hind limbs of rodents le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027C12Q1/68G01N33/573A01K67/02C12N9/10C12N15/85
CPCA01K67/02A01K67/0276A01K2217/075A01K2227/105A01K2267/03G01N2800/32C12N15/8509C12Q1/48G01N33/6893G01N2500/00C12N9/10
Inventor SHWORAK, NICHOLAS W.ROSENBERG, ROBERT D.PALAC, ROBERT T.ROSENBIRG, ROBERT D.
Owner TRUSTEES OF DARTMOUTH COLLEGE THE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com